Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies, which he notes are vital for moving the paradigm forward and ultimately improving patient outcomes.
Neal Shore, MD, FACS, highlights the efficacy data from the EMBARK study, toxicities observed with enzalutamide alone or in combination with a LHRH agonist, and the significance of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.
/PRNewswire/ Two months into the war, the implications and costs of the war are gradually coming to light – both physical and mental. The physical and.